Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.83 [0.65, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 92.2 % | low | not evaluable | high | crucial | - |
progression or deaths (PFS) | 0.76 [0.62, 0.93] | | < 1 | | 0% | 2 studies (2/-) | 99.7 % | low | not evaluable | high | important | - |
DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 1.00 [0.61, 1.66] | | > 1 | | 39% | 2 studies (2/-) | 50.7 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
AE (any grade) | 2.03 [0.18, 23.06] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 2.44 [1.17, 5.12] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.39 [0.51, 3.81] | | < 1 | | 0% | 2 studies (2/-) | 26.0 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (any grade) | 1.36 [0.42, 4.40] | | < 1 | | 84% | 2 studies (2/-) | 30.5 % | low | not evaluable | high | non important | - |
STRAE (any grade) | 1.24 [0.85, 1.81] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.12 [0.33, 3.77] | | < 1 | | 0% | 2 studies (2/-) | 42.8 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) | 2.12 [0.85, 5.29] | | < 1 | | 78% | 2 studies (2/-) | 5.3 % | low | not evaluable | high | non important | - |
TRAE leading to death (grade 5) | 2.02 [0.07, 61.28] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 2.67 [1.18, 6.03] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Arthralgia TRAE (grade 3-4) | 1.44 [0.48, 4.34] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 2.47 [0.45, 13.60] | | < 1 | | 0% | 1 study (1/-) | 15.1 % | NA | not evaluable | | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.30 [0.01, 6.77] | | < 1 | | 0% | 1 study (1/-) | 77.1 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.53 [0.16, 1.76] | | < 1 | | 0% | 1 study (1/-) | 84.8 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 3.70 [0.38, 35.82] | | < 1 | | 0% | 1 study (1/-) | 13.1 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.36 [0.78, 2.37] | | < 1 | | 0% | 1 study (1/-) | 14.1 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 2.46 [0.22, 27.26] | | < 1 | | 0% | 1 study (1/-) | 23.4 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.17 [0.02, 1.40] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 2.46 [0.22, 27.26] | | < 1 | | 0% | 1 study (1/-) | 23.4 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 1.22 [0.24, 6.13] | | < 1 | | 0% | 1 study (1/-) | 40.3 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.98 [0.53, 1.81] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.48 [0.09, 2.52] | | < 1 | | 0% | 1 study (1/-) | 80.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |